Orexigen Therapeutics (OREX) announced that it has entered into an agreement with Valeant Pharmaceuticals (VRX) unit Valeant Canada for the commercialization of obesity med Contrave (naltrexone HCl) in Canada. According to the terms of the agreement, Valeant Canada will be responsible for securing Canadian regulatory approval and all commercialization activities and expenses. Orexigen will supply Contrave at a specific transfer price and will be eligible for certain regulatory- and sales-based milestone payments. Specific financial terms are not disclosed. The marketing application to Health Canada should be filed in January 2017.